PRD001 / PRD Therapeutics - LARVOL DELTA

Synergy of SOAT2-inhibitor PRD001 with resmetirom in reducing MASH and fibrosis in obese Ldlr-/-.Leiden mice (EASL 2026) - "Using an advanced translational MASH model, we demonstrate resmetirom improved MASH and hepatic fibrosis. Adding PRD001 provided additional benefits on cholesterol excretion, plasma lipids, lipoproteins and steatosis highlighting the complementary mechanisms of PRD001 and resmetirom. Given the CVD risk in MASH patients, the observed lowering of atherogenic lipoproteins underscore substantial clinical advantages for the combination treatment."

Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • APOB

A First-in-Human Study of PRD001 (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: PRD Therapeutics, Inc.

New P1 trial

PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001 (Businesswire) - "PRD Therapeutics...announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor....'PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity'....This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers."

Trial status • Homozygous Familial Hypercholesterolemia